Abstract
Objectives: To evaluate the initial results of tenofovir in chronic hepatitis B patients with clinical change, rate of ALT change, HBeAg seroconversion and HBV DNA change after 12 months and determine virus break throught rate and side effects of tenofovir. Subjects and Methods: prospective study, open label, uncontrolled. Subjects: 75 Patients with chronic hepatitis B were enrolled in this study, treated with tenofovir in 12 months at Hue Medical University Hospital from 11/2010 to 8/2012. Results: The rate of ALT normalization is 77.3% after 6 months, 89.3% after 12 months. HBeAg loss rate is 22% after 6 months and 68.3% after 12 months. HBeAg seroconversion rate is 12.2% after 6 months and 29.3% after 12 months. HBV DNA-negative rate after 12 months is 84%. Low rate of side effects and not detected viral break-out. Conclusion: Tenofovir may be an effective and safe agent in patients with chronic hepatitis B.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
